.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The INPULSIS trials established the antifibrotic nintedanib as a disease-modifying treatment for idiopathic pulmonary fibrosis. Across two randomized, placebo-controlled studies, nintedanib significantly reduced the annual rate of decline in forced vital capacity compared with placebo. The drug did not reverse established fibrosis; its value was in slowing functional deterioration. Diarrhea was a common adverse effect and an important practical issue for treatment persistence. For HCPs, the paper supports early consideration of antifibrotic therapy once the diagnosis of IPF is established and an appropriate multidisciplinary assessment has been completed. It also reinforces the need to distinguish disease-modifying treatment from symptom-focused care, pulmonary rehabilitation, and management of comorbidities—each remains important even when antifibrotic therapy is started. The evidence fits the conference’s ILD program, particularly the emphasis on antifibrotics and longitudinal assessment. A useful clinical habit is to follow trajectory rather than a single FVC value, combining serial lung function, symptoms, oxygenation, imaging, and functional status when assessing progression and response.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The INPULSIS trials established the antifibrotic nintedanib as a disease-modifying treatment for idiopathic pulmonary fibrosis. Across two randomized, placebo-controlled studies, nintedanib significantly reduced the annual rate of decline in forced vital capacity compared with placebo. The drug did not reverse established fibrosis; its value was in slowing functional deterioration. Diarrhea was a common adverse effect and an important practical issue for treatment persistence. For HCPs, the paper supports early consideration of antifibrotic therapy once the diagnosis of IPF is established and an appropriate multidisciplinary assessment has been completed. It also reinforces the need to distinguish disease-modifying treatment from symptom-focused care, pulmonary rehabilitation, and management of comorbidities—each remains important even when antifibrotic therapy is started. The evidence fits the conference’s ILD program, particularly the emphasis on antifibrotics and longitudinal assessment. A useful clinical habit is to follow trajectory rather than a single FVC value, combining serial lung function, symptoms, oxygenation, imaging, and functional status when assessing progression and response.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
